Humana (HUM) Cost of Revenue (2009 - 2026)

Humana (HUM) has reported Cost of Revenue for 18 consecutive years, with $35.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 28.31% year-over-year to $35.4 billion in Q2 2026; TTM through Jun 2026 was $125.8 billion, a 20.26% increase from a year earlier, with the FY2025 full-year figure at $110.8 billion, up 10.08% from the prior year.
• Cost of Revenue was $35.4 billion for Q2 2026 at Humana, up from $33.7 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $35.4 billion in Q2 2026 and troughed at $18.4 billion in Q3 2022.
• A 5-year average of $24.7 billion and a median of $25.1 billion in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue increased 5.62% in 2025 and gained 28.31% in 2026, its largest moves.
• Over 5 years, Cost of Revenue stood at $18.6 billion in 2022, then climbed by 22.6% to $22.8 billion in 2023, then grew by 11.41% to $25.4 billion in 2024, then advanced by 13.16% to $28.7 billion in 2025, then rose by 23.15% to $35.4 billion in 2026.
• The last three Cost of Revenue figures came in at $35.4 billion (Q2 2026), $33.7 billion (Q1 2026), and $28.7 billion (Q4 2025), per Business Quant data.